Replies to This Discussion

Permalink Reply by luggnutz on August 4, 2009 at 11:31am

http://www.bio-medicine.org/biology-technology-1/NOVAVAX-Announces-...

NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
H1N1 virus-like Particle (VLP) Vaccine Candidate Based on the 1918 Spanish Influenza Strain Protected Mice and Ferrets Against the Spanish Flu and Highly Pathogenic H5N1 Bird Flu

ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today reported preclinical study results showing that an investigational H1N1 virus-like particle (VLP) vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain. The study, published in the March 25, 2009 online issue of the Journal of Virology, was conducted by scientists from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA and novavax under a Collaborative Research and Development Agreement.
Novavax scientists designed and produced a recombinant VLP vaccine candidate against the 1918 H1N1 influenza strain. This 1918 influenza strain was responsible for more than 50 million deaths worldwide during the great Spanish flu pandemic. Mice and ferrets were vaccinated with VLPs by one of two routes: either by standard intramuscular injection or by administering a small drop of the VLP vaccine in the nose (intranasal immunization). All of the 1918 VLP-immunized animals were protected when exposed to a lethal dose of the 1918 influenza virus, regardless of the route by which the vaccine was administered. Remarkably, animals immunized by the intranasal route were also protected against a lethal dose of a contemporary, highly pathogenic avian influenza subtype H5N1 virus strain, isolated from a fatal human case in 2004 (A/Vietnam/1203/2004 strain).
The H1N1 VLP vaccine candidate was made up of the hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins from 1918 Spanish influenza virus strains. These proteins, which were produced in insect cells, formed three-dimensional structures that mimic the 1918 pandemic influenza virus but without the genetic material needed for replication. The mechanism of action by which this H1N1 VLP vaccine candidate provided broad cross-protection is under further study, but the scientists described preliminary evidence that antibody cross-reactivity between the HA and possibly NA proteins of the H1N1 and H5N1 influenza were important.
"Unlike other non-live influenza vaccines, the VLPs are uniquely positioned to stimulate immunity through multiple mechanisms," said Dr. Penny Heaton, Chief Medical Officer at novavax. "First, they contain HA protein that is the same structure as the live virus, which may stimulate HA antibodies of several types that not only prevent the virus from attaching to cells but also prevent the virus from fusing with cells. Second, the VLPs contain NA which may stimulate production of antibody that prevents spread of the virus down the respiratory tract. Finally, the structure of the HA and NA proteins and the way in which they are embedded in lipids on the surface of the VLP may activate the innate immune system providing protection against both the H1N1 and H5N1 strains," said Dr. Heaton.
Although cross protection against influenza strains of the same hemagglutinin or HA type has been achieved through the use of vaccines with adjuvants (e.g., cross-protection against H5N1 A/Vietnam and A/Indonesia strains), protection against strains with different HA types, as shown in this study, has not been reported. Cross-protection against different HA types is highly desirable for pandemic influenza vaccine candidates because it is not possible to predict the strain that may be responsible for the next pandemic with today's technology. A broadly cross-protective vaccine would be ideal for stockpiling in that it could be administered during the first wave of the pandemic while waiting for manufacture of vaccine specific to the pandemic strain.
Dr. Gale Smith, Vice President of Vaccine Development at novavax, said, "The discovery that a VLP-based influenza vaccine candidate created through cell-based recombinant technology has the potential to protect against diverse strains of influenza has significant implications for both pre-pandemic and pandemic preparedness. A broadly protective vaccine administered prior to and during the first wave of a pandemic could prevent widespread morbidity and mortality from a newly emerged pandemic influenza strain and allow time for the development of strain-specific vaccines."
About novavax
Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary VLP technology. The company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. The Company has VLP vaccine candidates against seasonal influenza and potential pandemic influenza strains in phase II clinical development.
This report describes the second of two preclinical studies of novavax's investigational H5N1 pandemic influenza vaccine announced this year that have shown different approaches to achieving broad protection against diverse influenza strains. As announced in February, a VLP vaccine with an HA based on several H5 strains showed broad cross-protection against different H5 strains. In the current study, an alternative route of administration resulted in cross-protection against different HA types. novavax has shown in clinical trials that an H5N1 VLP candidate vaccine given by intramuscular injection is well tolerated and immunogenic in humans. Preclinical research on alternative pandemic influenza VLP vaccine approaches is expected to continue.
Additional information about novavax is available at

SOURCE novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

So we have Baxter spreading in Europe live Avian, we have this doctor pointing at Novartis, and I have this press release from Novavax. Far as I'm concerned, pointing at and choosing puppets to stab is useless. W.H.O. and ALL BIG PHARMA and MANY BIO LABS WORLDWIDE as well as all shadow governments are involved in this. It's the same eugenicists from the last 2 wars, U.N. and League of Nations.

I have full faith in MY RESEARCH and what Jehovah has led me to find. Puppets........they ALL WORK FOR LUCIFER! Face it, or shove your head you know where.....

Permalink Reply by truth on August 4, 2009 at 12:42pm

Key questions here:

Why don’t you provide the case number of the lawsuit and the court where it has been filed.

Not ‘will be filed,’ but the actual lawsuit so I can look at the documents?

What criminal charges with the FBI? I have not seen a single letter or court document to the FBI. I could care less about the joke called the “World Health Organization or the communist UN.

Prepared an injunction against forced vaccination in the US. Fine. Where is this injunction?

Permalink Reply by truth on August 4, 2009 at 1:52pm

If you know some one who speaks and or can write German, I have contact info for the head of the Austrian Health dept that Jane claims she sent the info (so called charges) too. Perhaps we can get some verification from them.

Why would Jane need any mainstream news coverage, every so called "truth" site in the world has given her unbelievable coverage.

I read so very much online that I believe I have gained enough insight to smell out a rat. I have nothing more than this hunch at this moment. Any secondary confirmation of her work would help, yet there isn't one.